• Publications
  • Influence
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.
Well-differentiated neuroendocrine tumors (NETs) of the stomach and pancreas represent 2 major subtypes of gastrointestinal NETs. Historically, there has been little consensus on the classificationExpand
  • 421
  • 20
  • PDF
Consensus guidelines for the management and treatment of neuroendocrine tumors.
Neuroendocrine tumors are a heterogeneous group of tumors originating in various anatomic locations. The management of this disease poses a significant challenge because of the heterogeneous clinicalExpand
  • 346
  • 20
The NANETS Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors (NETs): Well-Differentiated NETs of the Distal Colon and Rectum
Neuroendocrine tumors (NETs) of the distal colon and rectum are also known as hindgut carcinoids based on their common embryologic derivation. Their annual incidence in the United States is rising,Expand
  • 175
  • 15
  • PDF
Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies.
Somatostatin and its analogues bind to somatostatin receptors (sst) 1 through 5 that are overexpressed in neuroendocrine neoplasms such as gastroenteropancreatic (GEP) malignancies. AfterExpand
  • 247
  • 12
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.
Purpose Preliminary studies suggested that telotristat ethyl, a tryptophan hydroxylase inhibitor, reduces bowel movement (BM) frequency in patients with carcinoid syndrome. This placebo-controlledExpand
  • 154
  • 12
  • PDF
Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
A new treatment modality for inoperable or metastasized gastroenteropancreatic tumors is the use of radiolabeled somatostatin analogs. Initial studies with high doses ofExpand
  • 346
  • 10
  • PDF
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.
Pasireotide (SOM230) is a novel multireceptor-targeted somatostatin (sst) analog with high binding affinity for sst receptor subtype 1, 2, 3 (sst(1,2,3)) and sst(5). Because of this binding profile,Expand
  • 153
  • 9
  • PDF
Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin.
Studies were performed in 13 healthy subjects to determine whether treatment with rifampicin results in induction of the metabolism of mephenytoin. Daily dosing with 600 mg rifampicin for 22 daysExpand
  • 97
  • 6
Somatostatin analogue phase I trials in neuroendocrine neoplasms.
To further investigate the antineoplastic efficacy and safety of somatostatin analogues, 2 trials were performed. Octreotide, SMS 201-995 (Sandostatin), was escalated in doses ranging from 1,500Expand
  • 103
  • 6
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial
Telotristat ethyl, a tryptophan hydroxylase inhibitor, was efficacious and well tolerated in the phase 3 TELESTAR study in patients with carcinoid syndrome (CS) experiencing ≥4 bowel movements perExpand
  • 45
  • 5
  • PDF